A major 18-month human drug trial gets under way this week to see whether a blood pressure medication can slow or halt the progression of Alzheimers disease symptoms
The study - NILVAD (nilvadipine in Alzheimers disease) involves nine countries and has funding worth 6 million provided by the European Communitys seventh framework programme research budget.
There has been no new drug for the treatment of Alzheimers since 2002 and many originally promising lines of research for new treatments have come to nothing.
More information available at the links below: